AbobotulinumtoxinA potentiates the effect of trifluoperazine through pharmacodynamic synergism. Caution/Monitoring. Use of anticholinergic medicinal products following administration of products containing botulinum toxin may potentiate systemic anticholinergic effects.
Aclidinium decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of aclidinium through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Both acrivastine and trifluoperazine increase sedation. Caution/Monitoring.
trifluoperazine, albiglutide. Other (see comment). Caution/Monitoring. Comment: Phenothiazines can increase or decrease glucose levels. If these active ingredients are used concomitantly, the therapy should be closely monitored.
Trifluoperazine increases and albuterol decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.
Alfentanil and trifluoperazine increase sedation. Caution/Monitoring.
Almotriptan, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Both alprazolam and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine increases the toxicity of amifampridine to others (see comment). Adjust/monitor therapy closely. Comment: Amifampridine can cause convulsions. Concomitant use with drugs that lower the seizure threshold may increase this risk.
Trifluoperazine and amisulpride prolong the QTc interval. Caution/Monitoring. ECG monitoring is recommended when used concomitantly.
Trifluoperazine and amitriptyline increase sedation. Caution/Monitoring.
Amobarbital and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine and amoxapine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Adjust/monitor therapy closely.Trifluoperazine and amoxapine increase sedation. Caution/Monitoring.
Anagrelide and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Anticholinergic/sedative combinations decrease trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Combinations of anticholinergics and sedatives decrease trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effects of anticholinergic/sedative combinations through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Trifluoperazine and apomorphine increase sedation. Caution/Monitoring.
Trifluoperazine increases and arformoterol decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.
Aripiprazole and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Aripiprazole and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine increases and armodafinil decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.
Artemether/lumefantrine increases the level or effect of trifluoperazine by affecting the metabolism of the liver enzyme CYP2D6. Caution/Monitoring.
Asenapine and trifluoperazine increase sedation. Caution/Monitoring.
Transdermal asenapine and trifluoperazine increase sedation. Caution/Monitoring.
Atracurium decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Atracurium decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of atracurium through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Atropine decreases trifluoperazine levels by inhibiting GI absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Atropine decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effects of atropine through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Trifluoperazine potentiates the effects of IV/IM atropine through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.IV/IM atropine decreases trifluoperazine levels by inhibiting GI absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.IV/IM atropine decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.
Azelastine and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine and azithromycin prolong the QTc interval. Caution/Monitoring.
Baclofen and trifluoperazine increase sedation. Caution/Monitoring.
Belladonna alkaloids decrease trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Belladonna alkaloids decrease trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effects of belladonna alkaloids through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Belladonna and opium and trifluoperazine increase sedation. Caution/Monitoring.Belladonna and opium decrease trifluoperazine levels by inhibiting GI absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Belladonna and opium decrease trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effects of belladonna and opium through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Benperidol and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Benperidol and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine increases and benzphetamine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, benzphetamine. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
Trifluoperazine potentiates the effects of benzotropine through pharmacodynamic synergism. Caution/Monitoring. With simultaneous use, additional anticholinergic side effects may be observed. .
brexanolone, trifluoperazine. Both increase the toxicity of the other through sedation. Caution/Monitoring.
Brompheniramine and trifluoperazine increase sedation. Caution/Monitoring.
Buprenorphine and trifluoperazine increase sedation. Caution/Monitoring.Buprenorphine and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Oral buprenorphine and trifluoperazine increase sedation. Caution/Monitoring.
Subdermal implantation of buprenorphine and trifluoperazine shortens the QTc interval. Caution/Monitoring.
transdermal buprenorphine and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Trifluoperazine increases the toxicity of long-acting buprenorphine for injection through pharmacodynamic synergy. Adjust/monitor therapy closely. Concomitant use of buprenorphine and benzodiazepines or other CNS depressants increases the risk of adverse events, including overdose, respiratory depression, and death. Discontinuation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher treatment level may be appropriate to taper CNS depressants. In other cases, it may be appropriate to gradually reduce or reduce to the lowest effective dose the patient's prescribed benzodiazepines or other CNS depressants.Buprenorphine, long-acting injections, and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Bupropion increases the level or effect of trifluoperazine by affecting the metabolism of the liver enzyme CYP2D6. Caution/Monitoring.
Butabarbital and trifluoperazine increase sedation. Caution/Monitoring.
Butalbital and trifluoperazine increase sedation. Caution/Monitoring.
Butorphanol and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine increases and caffeine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.
cannabidiol, trifluoperazine. affect the metabolism of the liver enzyme CYP1A2. Adjust/monitor therapy closely. Due to the potential for CYP1A2 induction and inhibition with concomitant administration of CYP1A2 substrates and cannabidiol, a reduction in dose adjustment of CYP1A2 substrates should be considered when clinically appropriate.
Carbinoxamine and trifluoperazine increase sedation. Caution/Monitoring.
Carisoprodol and trifluoperazine increase sedation. Caution/Monitoring.
cenobamate, trifluoperazine. Both enhance the effect of the other through sedation. Caution/Monitoring.
Chloral hydrate and trifluoperazine increase sedation. Caution/Monitoring.
Chlordiazepoxide and trifluoperazine increase sedation. Caution/Monitoring.
Chlorpheniramine and trifluoperazine increase sedation. Caution/Monitoring.
Chlorpromazine and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Chlorpromazine and trifluoperazine increase sedation. Caution/Monitoring.
Chlorzoxazone and trifluoperazine increase sedation. Caution/Monitoring.
Cigarette smoking lowers trifluoperazine levels by increasing metabolism. Caution/Monitoring. The interaction is mainly observed with chlorpromazine and thioridazine, but can also occur with other phenothiazines.
Cinnarizine and trifluoperazine increase sedation. Caution/Monitoring.
Cisatracurium decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Cisatracurium decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of cisatracurium through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Clemastine and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine and clomipramine increase sedation. Caution/Monitoring.
Clonazepam and trifluoperazine increase sedation. Caution/Monitoring.
clonidine, trifluoperazine. Mechanism: pharmacodynamic synergism. Use caution/monitoring. additional antihypertensive effects; potential delirium.
Clorazepate and trifluoperazine increase sedation. Caution/Monitoring.
Clozapine and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Clozapine and trifluoperazine increase sedation. Caution/Monitoring.
Codeine and trifluoperazine increase sedation. Caution/Monitoring.
Cyclizine and trifluoperazine increase sedation. Caution/Monitoring.Cyclizine decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Cyclizine lowers trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the action of cyclizine through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Cyclobenzaprine and trifluoperazine increase sedation. Caution/Monitoring.Cyclobenzaprine decreases trifluoperazine levels by inhibiting GI absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Cyclobenzaprine decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effects of cyclobenzaprine through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Cyproheptadine and trifluoperazine increase sedation. Caution/Monitoring.
Dantrolene and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine and daridorexant increase sedation. Adjust/monitor therapy closely. Concomitant use increases the risk of CNS depression, which can lead to additional impairment of psychomotor performance and impairment of time of day.
Darifenacin decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Darifenacin decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of darifenacin through pharmacodynamic synergy. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Trifluoperazine and dasatinib prolong the QTc interval. Adjust/monitor therapy closely.
Desflurane and trifluoperazine increase sedation. Caution/Monitoring.Desflurane and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Trifluoperazine and desipramine increase sedation. Caution/Monitoring.
Desvenlafaxine increases the level or effect of trifluoperazine by affecting the metabolism of the liver enzyme CYP2D6. Caution/Monitoring. Desvenlafaxine inhibits CYP2D6; at higher doses of desvenlafaxine (ie 400 mg), reduce the dose of the CYP2D6 substrate by up to 50%; No dose adjustment is required for desvenlafaxine doses < 100 mg
Trifluoperazine and deuterabenazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Adjust/monitor therapy closely. The risk of parkinsonism, neuroleptic malignant syndrome and akathisia may be increased by concomitant use of deutetrabenazine and dopamine antagonists or antipsychotics.Trifluoperazine and deutetrabenazine increase sedation. Caution/Monitoring.Deutetrabenazine and trifluoperazine shorten the QTc interval. Caution/Monitoring. At the maximum recommended dose, deutetrabenazine does not prolong the QT interval to a clinically relevant extent. Certain conditions may increase the risk of torsades de pointes and/or sudden cardiac death associated with medicinal products that prolong the QTc interval (e.g. bradycardia, hypokalemia or hypomagnesaemia, concomitant use with other medicinal products that prolong the QTc interval, presence of congenital QT). .
Dexchlorpheniramine and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine increases and dexfenfluramine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, dexfenfluramine. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
Dexmedetomidine and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine increases and dexmethylphenidate decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, dexmethylphenidate. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
Trifluoperazine increases and dextroamphetamine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, dextroamphetamine. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
dextromethorphan, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Dextromoramide and trifluoperazine increase sedation. Caution/Monitoring.
Diamorphine and trifluoperazine increase sedation. Caution/Monitoring.
Both diazepam and trifluoperazine increase sedation. Caution/Monitoring.
Dicyclomine decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Dicyclomine decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the action of dicyclomine through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Trifluoperazine increases and diethylpropion decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, diethylpropion. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
Diphekephalin and trifluoperazine increase sedation. Caution/Monitoring.
Diphenoxin hcl and trifluoperazine increase sedation. Caution/Monitoring.
dihydroergotamine, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Dimenhydrinate and trifluoperazine increase sedation. Caution/Monitoring.
Diphenhydramine and trifluoperazine increase sedation. Caution/Monitoring.Diphenhydramine decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Diphenhydramine decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of diphenhydramine through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Diphenoxylate HCl and trifluoperazine increase sedation. Caution/Monitoring.
Dipipanone and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine increases and dobutamine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, dobutamine. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
Trifluoperazine and dolasetron prolong the QTc interval. Adjust/monitor therapy closely.
Donepezil and trifluoperazine shorten the QTc interval. Caution/Monitoring.
transdermal donepezil, trifluoperazine. Both reduce the effects of the other through pharmacodynamic antagonism. Caution/Monitoring.
Trifluoperazine increases and dopamine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, dopamine. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
Trifluoperazine increases and dopexamine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.
Trifluoperazine and dosulepin increase sedation. Caution/Monitoring.
Trifluoperazine and doxepin increase sedation. Caution/Monitoring.
Doxylamine and trifluoperazine increase sedation. Caution/Monitoring.
Droperidol and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Droperidol and trifluoperazine increase sedation. Caution/Monitoring.
Efavirenz and trifluoperazine shorten the QTc interval. Caution/Monitoring.
eletriptan, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Eliglustat and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Encorafenib and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Entrectinib and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Trifluoperazine increases and ephedrine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, ephedrine. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
Trifluoperazine increases and epinephrine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, epinephrine. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.Trifluoperazine reduces the effect of epinephrine through pharmacodynamic antagonism. Caution/Monitoring. Blocks the pressor response to epinephrine, which can result in severe hypotension and tachycardia.
Trifluoperazine increases and racemic epinephrine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.Trifluoperazine reduces the effect of racemic epinephrine through pharmacodynamic antagonism. Caution/Monitoring. Blocks the pressor response to epinephrine, which can result in severe hypotension and tachycardia.
ergoloid mesylates, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
ergotamine, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Eribulin and trifluoperazine shorten the QTc interval. Caution/Monitoring.
intranasal esketamine, trifluoperazine. Both increase the toxicity of the other through sedation. Adjust/monitor therapy closely.
Estazolam and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine and ethanol increase sedation. Caution/Monitoring.
Etomidate and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine increases and fenfluramine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, fenfluramine. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
fentanyl, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Fesoterodine decreases trifluoperazine levels by inhibiting GI absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Fesoterodine decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of fesoterodine through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Fexinidazole increases the level or effect of trifluoperazine by affecting the metabolism of the liver enzyme CYP1A2. Caution/Monitoring.
Fingolimod and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Flavoxate decreases trifluoperazine levels by inhibiting GI absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Flavoxate decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the action of flavoxate through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Trifluoperazine and flecainide prolong the QTc interval. Adjust/monitor therapy closely.
flibanserin, trifluoperazine. affect the metabolism of the liver/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Fluoxetine increases the level or effect of trifluoperazine by affecting the metabolism of the liver enzyme CYP2D6. Caution/Monitoring.Trifluoperazine and fluoxetine prolong the QTc interval. Adjust/monitor therapy closely.
Fluphenazine and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Fluphenazine and trifluoperazine increase sedation. Caution/Monitoring.
Flurazepam and trifluoperazine increase sedation. Caution/Monitoring.
Fluvoxamine and trifluoperazine prolong the QTc interval. Adjust/monitor therapy closely.
Trifluoperazine increases and formoterol decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.
Trifluoperazine and foscarnet prolong the QTc interval. Adjust/monitor therapy closely.
frovatriptan, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Trifluoperazine and ganaxolone increase sedation. Caution/Monitoring.
Gemifloxacin and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Gilteritinib and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Trifluoperazine potentiates the action of glycopyrrolate through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Inhaled glycopyrrolate decreases trifluoperazine levels by inhibiting GI absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Inhaled glycopyrrolate decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of inhaled glycopyrrolate through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
topical glycopyrronium tosylate, trifluoperazine. Each enhances the effects of the other through pharmacodynamic synergism. Caution/Monitoring. Concomitant use of topical glycopyrronium tosylate with other anticholinergic drugs may result in additional anticholinergic side effects.
Granisetron and trifluoperazine shorten the QTc interval. Caution/Monitoring.
guanfacine, trifluoperazine. Mechanism: pharmacodynamic synergism. Use caution/monitoring. additional antihypertensive effects; potential delirium.
Haloperidol and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Haloperidol and trifluoperazine increase sedation. Caution/Monitoring.
Henbane lowers trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Henbane lowers trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the action of henbane through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Homatropin decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Homatropin decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of homatropine through pharmacodynamic synergy. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Hydromorphone and trifluoperazine increase sedation. Caution/Monitoring.
Hydroxyzine and trifluoperazine increase sedation. Caution/Monitoring.Hydroxyzine and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Hyoscyamine decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Hyoscyamine decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the action of hyoscyamine through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Trifluoperazine potentiates the action of hyoscyamine spray through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.Hyoscyamine aerosol reduces trifluoperazine levels by inhibiting GI absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Hyoscyamine aerosol reduces trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.
Both iloperidone and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Trifluoperazine and iloperidone prolong the QTc interval. Adjust/monitor therapy closely.Iloperidone and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine and imipramine increase sedation. Caution/Monitoring.
Trifluoperazine potentiates the effect of incobotulinum toxin A through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Indacaterol, inhaled, trifluoperazine. QTc interval. Caution/Monitoring. Drugs known to prolong the QTc interval may increase the risk of ventricular arrhythmias.
Trifluoperazine reduces the effect of insulin degludec by others (see comment). Caution/Monitoring. Comment: Phenothiazines can increase blood sugar concentration.
Trifluoperazine reduces the effect of insulin degludec/insulin aspart by others (see comment). Caution/Monitoring. Comment: Phenothiazines can increase blood sugar concentration.
Trifluoperazine decreases the effects of insulin inhaled by others (see comment). Caution/Monitoring. Comment: Phenothiazines can increase blood sugar concentration.
Ipratropium decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Ipratropium decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of ipratropium through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Isoflurane and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Trifluoperazine increases and isoproterenol decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, isoproterenol. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
Ketamine and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine and ketotifen, ophthalmic, increase sedation. Caution/Monitoring.
Trifluoperazine and lapatinib prolong the QTc interval. Adjust/monitor therapy closely.
Lasmiditan, trifluoperazine. Both enhance the effect of the other through sedation. Caution/Monitoring. The concomitant use of Lasmiditan and other CNS depressants, including alcohol, has not been studied in clinical studies. Lasmiditan can cause sedation as well as other cognitive and/or neuropsychiatric side effects.
lemborexant, trifluoperazine. Both enhance the effect of the other through sedation. Adjust/monitor therapy closely. Dose adjustment may be required when lemborexant is co-administered with other CNS depressant medicinal products due to potential additive effects.
Trifluoperazine increases and levalbuterol decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.
Trifluoperazine and levofloxacin prolong the QTc interval. Adjust/monitor therapy closely.
levomilnacipran, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Levorphanol and trifluoperazine increase sedation. Caution/Monitoring.
Linezolid, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
trifluoperazine, liraglutide. Other (see comment). Caution/Monitoring. Comment: Phenothiazines can increase or decrease glucose levels. If these active ingredients are used concomitantly, the therapy should be closely monitored.
Trifluoperazine increases and lisdexamfetamine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.Trifluoperazine, lisdexamfetamine. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
lithium, trifluoperazine. Other (see comment). Caution/Monitoring. Comment: risk of neurotoxicity. Several mechanisms involved.lithium, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).Lithium and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Trifluoperazine and lofepramine increase sedation. Caution/Monitoring.
Trifluoperazine and lofexidine increase sedation. Caution/Monitoring.
Both loprazolem and trifluoperazine increase sedation. Caution/Monitoring.
Lorazepam and trifluoperazine increase sedation. Caution/Monitoring.
lorcaserin, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Lormetazepam and trifluoperazine increase sedation. Caution/Monitoring.
Loxapine and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Loxapine and trifluoperazine increase sedation. Caution/Monitoring.
Inhaled loxapine and trifluoperazine potentiate the antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Inhaled loxapine and trifluoperazine increase sedation. Caution/Monitoring.
Lumefantrine increases the level or effect of trifluoperazine by affecting the metabolism of the liver enzyme CYP2D6. Caution/Monitoring.
lurasidone, trifluoperazine. Or it increases the toxicity of the other to the other (see comment). Caution/Monitoring. Comment: Potential for increased CNS depressant effects with concomitant use; Monitoring for increased side effects and toxicity.
Trifluoperazine and maprotiline increase sedation. Caution/Monitoring.
Trifluoperazine and marijuana increase sedation. Caution/Monitoring.
Meclizine decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Meclizine decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the action of meclizine through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Trifluoperazine and melatonin increase sedation. Caution/Monitoring.
Meperidine and trifluoperazine increase sedation. Caution/Monitoring.meperidine, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Trifluoperazine and meprobamate increase sedation. Caution/Monitoring.
Trifluoperazine increases and metaproterenol decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.
Metaxalone and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine decreases the effect of metformin through pharmacodynamic antagonism. Caution/Monitoring. The patient should be closely monitored for loss of glycemic control; When medication is discontinued in a patient receiving metformin, the patient should be carefully monitored for hypoglycemia.
Trifluoperazine and methadone prolong the QTc interval. Adjust/monitor therapy closely.Methadone and trifluoperazine increase sedation. Caution/Monitoring.methadone, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Trifluoperazine increases and methamphetamine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, methamphetamine. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
Methocarbamol and trifluoperazine increase sedation. Caution/Monitoring.
methoxsalen, trifluoperazine. Each increases the toxicity of the other through pharmacodynamic synergism. Caution/Monitoring. Additive photosensitizing effects.
Methscopolamine decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Methscopolamine decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of methscopolamine through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Trifluoperazine increases and methylenedioxymethamphetamine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, methylenedioxymethamphetamine. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
methylergonovine, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
trifluoperazine, methylphenidate. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.Trifluoperazine increases the toxicity of methylphenidate through pharmacodynamic antagonism. Caution/Monitoring. When these medicinal products are used in combination, close monitoring should be done for evidence of an impaired clinical response to methylphenidate or an antipsychotic.
Trifluoperazine and metoclopramide potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.
Midazolam and trifluoperazine increase sedation. Caution/Monitoring.
intranasal midazolam, trifluoperazine. Both enhance the toxicity of the other through pharmacodynamic synergism. Adjust/monitor therapy closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and contribute to a potent and/or sustained drug effect.
Trifluoperazine increases and midodrine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, midodrine. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
Milnacipran, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Trifluoperazine and mirtazapine increase sedation. Caution/Monitoring.Mirtazapine and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Trifluoperazine increases and modafinil decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.
Morphine and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine and motherwort increase sedation. Caution/Monitoring.
Trifluoperazine and moxonidine increase sedation. Caution/Monitoring.
Trifluoperazine and nabilone increase sedation. Caution/Monitoring.
Nalbuphine and trifluoperazine increase sedation. Caution/Monitoring.
Naratriptan, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Trifluoperazine increases and norepinephrine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, norepinephrine. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
Trifluoperazine and nortriptyline increase sedation. Caution/Monitoring.
Trifluoperazine and ofloxacin prolong the QTc interval. Adjust/monitor therapy closely.
Olanzapine and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Olanzapine and trifluoperazine increase sedation. Caution/Monitoring.Olanzapine and trifluoperazine shorten the QTc interval. Caution/Monitoring.
glyceridine, trifluoperazine. Each increases the toxicity of the other through pharmacodynamic synergism. Adjust/monitor therapy closely. With simultaneous use, deep sedation, respiratory depression, coma and death may occur. Reserve the concomitant prescription of these drugs for patients unsuitable for other treatment options. Limit doses and duration to the minimum necessary. Pay close attention to signs of respiratory depression and sedation. Increased risk of hypotension when the ability to maintain blood pressure is impaired by decreased blood volume or concomitant administration of certain CNS depressants (e.g. phenothiazines or general anaesthetics).
Inhaled trifluoperazine and olodaterol prolong the QTc interval. Caution/Monitoring. Medicines that prolong the QTc interval and can increase the effects of beta2-agonists on the cardiovascular system; increased risk of ventricular arrhythmias
OnabotulinumtoxinA decreases trifluoperazine levels by inhibiting GI absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.OnabotulinumtoxinA decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the action of onabotulinum toxin A through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Tincture of opium and trifluoperazine increase sedation. Caution/Monitoring.
Orphenadrine and trifluoperazine increase sedation. Caution/Monitoring.
Oxaliplatin and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Oxazepam and trifluoperazine increase sedation. Caution/Monitoring.
Oxybutynin decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Oxybutynin decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effects of oxybutynin through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
topical oxybutynin decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.topical oxybutynin decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effects of topical oxybutynin through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
transdermal oxybutynin decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.transdermal oxybutynin decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of transdermal oxybutynin through pharmacodynamic synergy. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Oxycodone and trifluoperazine increase sedation. Caution/Monitoring.
Oxymorphone and trifluoperazine increase sedation. Caution/Monitoring.
Paliperidone and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Trifluoperazine and paliperidone prolong the QTc interval. Adjust/monitor therapy closely.Paliperidone and trifluoperazine increase sedation. Caution/Monitoring.
Pancuronium decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Pancuronium decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of pancuronium through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Papaveretum and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine and papaverine increase sedation. Caution/Monitoring.
Paroxetine increases the level or effect of trifluoperazine by affecting the metabolism of the liver enzyme CYP2D6. Caution/Monitoring.Trifluoperazine and paroxetine prolong the QTc interval. Adjust/monitor therapy closely.paroxetine, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Trifluoperazine and pazopanib prolong the QTc interval. Caution/Monitoring.
Pentazocine and trifluoperazine increase sedation. Caution/Monitoring.
Pentobarbital and trifluoperazine increase sedation. Caution/Monitoring.
Perphenazine and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Perphenazine and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine increases and phendimetrazine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, phendimetrazine. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
phenelzine, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Phenobarbital and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine increases and phentermine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, phentermine. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
Trifluoperazine increases and phenylephrine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, phenylephrine. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
Trifluoperazine increases and PO-phenylephrine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring. .trifluoperazine, phenylephrine PO. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
Trifluoperazine and pholcodine increase sedation. Caution/Monitoring.
Pimozide and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Pimozide and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine increases and pirbuterol decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.
trifluoperazine, porfimer. Mechanism: pharmacodynamic synergism. Caution/Monitoring. Improved light sensitivity.
Trifluoperazine and posaconazole prolong the QTc interval. Adjust/monitor therapy closely.
Pralidoxime decreases trifluoperazine levels by inhibiting GI absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Pralidoxime decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the action of pralidoxime through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Primaquine and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Primidone and trifluoperazine increase sedation. Caution/Monitoring.
procarbazine, trifluoperazine. Mechanism: pharmacodynamic synergism. Caution/Monitoring. Excessive sedation.procarbazine, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Prochlorperazine and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Prochlorperazine and trifluoperazine increase sedation. Caution/Monitoring.
Promethazine and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Promethazine and trifluoperazine increase sedation. Caution/Monitoring.promethazine, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Propafenone increases the level or effect of trifluoperazine by affecting the metabolism of the liver enzyme CYP2D6. Caution/Monitoring.
Propantheline decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Propantheline decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the action of propantheline through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Propofol and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine increases and propylhexedrine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, propylhexedrine. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
Trifluoperazine and protriptyline increase sedation. Caution/Monitoring.
trifluoperazine, pseudoephedrine. Mechanism: unknown. Caution/Monitoring. Consider avoiding the use of pseudoephedrine in patients receiving phenothiazines (particularly thioridazine) due to the potential risk of cardiac arrhythmia or sudden death. With simultaneous use, watch for signs of ventricular arrhythmias.
Quazepam and trifluoperazine increase sedation. Caution/Monitoring.
Quetiapine and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Quetiapine and trifluoperazine increase sedation. Caution/Monitoring.
Quinidine increases the level or effect of trifluoperazine by affecting the metabolism of the liver enzyme CYP2D6. Caution/Monitoring.
Trifluoperazine and Ramelteon increase sedation. Caution/Monitoring.
Trifluoperazine and ranolazine prolong the QTc interval. Adjust/monitor therapy closely.
Rapacuronium decreases trifluoperazine levels by inhibiting GI absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Rapacuronium decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of rapacuronium through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Remimazolam, trifluoperazine. Both increase the toxicity of the other through sedation. Adjust/monitor therapy closely. Concomitant use may result in severe sedation, respiratory depression, coma and/or death. When used concomitantly, vital signs should be continuously monitored during the sedation and recovery periods. Carefully titrate the dose of remizolam when co-administered with opioids and/or sedative/hypnotic analgesics.
Trifluoperazine, Rhymabotulinumtoxin B. Both potentiate the effects of the other through pharmacodynamic synergism. Caution/Monitoring. Anticholinergics can increase the effects of botulinum toxin. Monitor closely for increased neuromuscular blockade.
Risperidone and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Trifluoperazine and risperidone prolong the QTc interval. Adjust/monitor therapy closely.Risperidone and trifluoperazine increase sedation. Caution/Monitoring.
Rizatriptan, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Rocuronium decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Rocuronium decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of rocuronium through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Trifluoperazine and romidepsin prolong the QTc interval. Adjust/monitor therapy closely.
Rucaparib increases the level or effect of trifluoperazine by affecting the metabolism of the liver enzyme CYP1A2. Adjust/monitor therapy closely. Adjust the dose of CYP1A2 substrates as clinically indicated.
Trifluoperazine increases and salmeterol decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.
Scopolamine decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Scopolamine decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of scopolamine through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Trifluoperazine and skullcap increase sedation. Caution/Monitoring.
Both secobarbital and trifluoperazine increase sedation. Caution/Monitoring.
selegiline, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Trifluoperazine, serdex methylphenidate/dexmethylphenidate. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
Sertraline and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Sevoflurane and trifluoperazine increase sedation. Caution/Monitoring.Sevoflurane and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Trifluoperazine and shepherd's purse increase sedation. Caution/Monitoring.
Siponimod and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Smoking lowers trifluoperazine levels by increasing metabolism. Caution/Monitoring. The interaction is mainly observed with chlorpromazine and thioridazine, but can also occur with other phenothiazines.
Sodium sulfate/magnesium sulfate/potassium chloride potentiate the effects of trifluoperazine by an unknown mechanism. Caution/Monitoring. Watch closely for signs of increased CNS depression when higher doses of magnesium sulfate are used in conjunction with a CNS depressant.
Sodium sulfate/potassium sulfate/magnesium sulfate potentiate the effects of trifluoperazine by an unknown mechanism. Caution/Monitoring. Watch closely for signs of increased CNS depression when higher doses of magnesium sulfate are used in conjunction with a CNS depressant.
Solifenacin decreases trifluoperazine levels by inhibiting GI absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Solifenacin decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of solifenacin through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.Solifenacin and trifluoperazine shorten the QTc interval. Caution/Monitoring.
stiripentol, trifluoperazine. affect the metabolism of the liver enzyme CYP1A2. Adjust/monitor therapy closely. Stiripentol is a CYP1A2 inhibitor and inducer. Monitor CYP1A2 substrates co-administered with stiripentol for increased or decreased effects. Dose adjustment may be required for CYP1A2 substrates.
Sufentanil and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine and sulfamethoxazole prolong the QTc interval. Adjust/monitor therapy closely.
sumatriptan, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
intranasal sumatriptan, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Sunitinib and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Tacrolimus and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Tapentadol and trifluoperazine increase sedation. Caution/Monitoring.
Teduglutide increases trifluoperazine levels in others (see comment). Caution/Monitoring. Comment: Teduglutide may increase absorption of concomitant oral medications; Caution with drugs that require titration or with a narrow therapeutic index; Dose adjustment may be necessary.
Trifluoperazine and telavancin prolong the QTc interval. Adjust/monitor therapy closely.
Temazepam and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine increases and terbutaline decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.
Teriflunomide decreases trifluoperazine levels by affecting the metabolism of the liver enzyme CYP1A2. Caution/Monitoring.
Trifluoperazine and tetrabenazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Adjust/monitor therapy closely.
Thioridazine and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Thioridazine and trifluoperazine increase sedation. Caution/Monitoring.
Thiothixene and trifluoperazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Thiothixene and trifluoperazine increase sedation. Caution/Monitoring.
Tiotropium decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Tiotropium decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of tiotropium through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Tobacco use decreases trifluoperazine levels by increasing metabolism. Caution/Monitoring. The interaction is mainly observed with chlorpromazine and thioridazine, but can also occur with other phenothiazines.
Tolterodine decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Tolterodine decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of tolterodine through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Trifluoperazine and topiramate increase sedation. Adjust/monitor therapy closely.
Tramadol and trifluoperazine increase sedation. Caution/Monitoring.
tranylcypromine, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Trifluoperazine and trazodone increase sedation. Caution/Monitoring.
Triazolam and trifluoperazine increase sedation. Caution/Monitoring.
Triclofos and trifluoperazine increase sedation. Caution/Monitoring.
Trihexyphenidyl decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of trihexyphenidyl through pharmacodynamic synergism. Caution/Monitoring. Potential for additive anticholinergic effects.
Trifluoperazine and trimethoprim prolong the QTc interval. Adjust/monitor therapy closely.
Trifluoperazine and trimipramine increase sedation. Caution/Monitoring.
Triprolidine and trifluoperazine increase sedation. Caution/Monitoring.
Trifluoperazine and tropisetron prolong the QTc interval. Adjust/monitor therapy closely.
Trospium chloride decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Trospium chloride decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of trospium chloride through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Valbenazine and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Vecuronium decreases trifluoperazine levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both active ingredients. Caution/Monitoring.Vecuronium decreases trifluoperazine levels through pharmacodynamic antagonism. Caution/Monitoring.Trifluoperazine potentiates the effect of vecuronium through pharmacodynamic synergism. Caution/Monitoring. Additional anticholinergic effects, possible hypoglycemia.
Venlafaxine increases the level or effect of trifluoperazine by affecting the metabolism of the liver enzyme CYP2D6. Caution/Monitoring.Trifluoperazine and venlafaxine prolong the QTc interval. Adjust/monitor therapy closely.venlafaxine, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Vilazodone, trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Trifluoperazine and voriconazole prolong the QTc interval. Adjust/monitor therapy closely.
Vorinostat and trifluoperazine shorten the QTc interval. Caution/Monitoring.
Trifluoperazine increases and xylometazoline decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, xylometazoline. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
Trifluoperazine increases and yohimbine decreases sedation. The interaction effect is not clear, be careful. Caution/Monitoring.trifluoperazine, yohimbine. Mechanism: unknown. Caution/Monitoring. Risk of cardiac arrhythmias or sudden death, more likely with thioridazine than other phenothiazines. Interactions are more likely in certain predisposed patients. Only.
Trifluoperazine and ziconotide increase sedation. Caution/Monitoring.
Trifluoperazine and ziprasidone potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Trifluoperazine and ziprasidone increase sedation. Caution/Monitoring.
Zolmitriptan, Trifluoperazine. Mechanism of interaction not given. Caution/Monitoring. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotics can potentiate the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Trifluoperazine increases the level or effect of zolpidem through pharmacodynamic synergism. Adjust/monitor therapy closely. Additive effect of reduced attention and psychomotor performance
Trifluoperazine and zotepin potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Caution/Monitoring.Trifluoperazine and zotepine increase sedation. Caution/Monitoring.